ComboMATCH trials will use Exact Sciences' (EXAS) new OncoExTra™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials ...

Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer ...

Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...

Abbott plans to close its $21 billion acquisition of cancer test maker Exact Sciences on Monday. The companies announced on ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday ...

Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical ...

Exact SciencesEXAS stock crashed Wednesday after the company inked a deal for the exclusive rights to Freenome's blood-based colon cancer test. The news comes alongside a second-quarter beat-and-raise ...

On Sunday, Exact Sciences Corp (NASDAQ:EXAS) reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion. For 2024, the company expects ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...